CVS Caremark Now Covers Both Zepbound and Wegovy: What the Change Means for You

CVS just flipped the script on GLP-1 coverage — and if you’ve been stuck paying out of pocket because your plan dropped Zepbound, this matters.

What’s changing: CVS Caremark, one of the nation’s largest pharmacy benefit managers, will restore coverage of Eli Lilly’s Zepbound on October 1, 2026, and will add coverage of Lilly’s new obesity pill, Foundayo (orforglipron), on June 1, 2026. Both Lilly’s and Novo Nordisk’s GLP-1 medications will be co-preferred options on CVS’s standard commercial formulary — a move that affects roughly 25 to 30 million Americans.

Why it matters: Last year, CVS made Wegovy the preferred GLP-1 on its standard plans and dropped Zepbound coverage entirely. If you were on a CVS plan and wanted Lilly’s drug, you paid full price or jumped through prior authorization hoops. That just changed.

The catch: Plan sponsors — your employer or union — can still opt out of covering GLP-1s for weight loss. So “co-preferred” doesn’t automatically mean your plan covers it. But CVS estimates this shift will drive 10–15% savings across the weight management drug category.

What this means for your wallet: Competition between drugmakers is finally translating into real access. When CVS — a major PBM — puts both companies on equal footing, it forces pricing negotiations that benefit patients. This is how the market is supposed to work.

The bigger picture: For Medicare Part D beneficiaries, the GLP-1 Bridge program launches July 1, 2026, bringing a flat $50 monthly copay for Wegovy and Zepbound. See if you qualify for the Medicare GLP-1 Bridge. Between CVS’s commercial formulary update and Medicare’s new benefit, the GLP-1 access landscape is improving.

Your next step: If you’ve been waiting for better coverage, the window is opening. Contact your plan to confirm whether GLP-1s for weight loss are covered. And if you have Medicare — mark July 1 on your calendar.

Source: CVS Health press release, May 28, 2026